What does Grace Therapeutics, Inc. do?
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal…
What is Grace Therapeutics, Inc.'s P/E and P/B ratio?
Grace Therapeutics, Inc. has a P/E ratio of -1.6 and a P/B ratio of 0.84.
What is Grace Therapeutics, Inc.'s debt-to-equity ratio?
Grace Therapeutics, Inc. has a debt-to-equity ratio of 0.00.
How much does Grace Therapeutics, Inc. owe compared with what it owns?
Grace Therapeutics, Inc. owes $0.04 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Grace Therapeutics, Inc.'s Positivity rank?
Grace Therapeutics, Inc. is ranked #1,696 of 6,775 companies globally and #388 of 4,000 in United States on PositoAI, with a Positivity Score of 22,479.
Does Grace Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Grace Therapeutics, Inc..
Where can I read the latest news about Grace Therapeutics, Inc.?
Recent headlines about Grace Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Grace Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Grace Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.